Libtayo® (cemiplimab-rwlc) in combination with chemotherapy approved by the fda as first-line treatment for advanced non-small cell lung cancer (nsclc)

Approval based on superior survival outcomes of libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics second advanced nsclc indication expands patient population eligible for a libtayo-based regimen to include combination treatment with chemotherapy  irrespective of pd-l1 expression levels tarrytown, n.y. , nov. 8, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has approved the pd-1 inhibitor libtayo® (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (nsclc) with no egfr, alk or ros1 aberrations.
REGN Ratings Summary
REGN Quant Ranking